Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 4 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Macular Degeneration Asia-Pacific Market to 2019 Introduction | 10 | 18 |
| Symptoms | 10 | 1 |
| Etiology | 11 | 1 |
| Pathophysiology | 11 | 1 |
| Disease Initiation | 12 | 1 |
| Disease Propagation | 12 | 1 |
| Dry AMD | 12 | 1 |
| Wet AMD | 12 | 2 |
| Classification | 14 | 1 |
| Early AMD | 14 | 1 |
| Intermediate AMD | 14 | 1 |
| Advanced AMD | 15 | 1 |
| Geographic Atrophy | 15 | 1 |
| Wet AMD | 15 | 1 |
| Co-morbidities and Complications | 16 | 1 |
| Diagnosis | 17 | 1 |
| History | 17 | 1 |
| Examination | 17 | 1 |
| Amsler Grid | 17 | 1 |
| Visual Acuity Testing | 18 | 1 |
| Slit Lamp Microscopy | 18 | 1 |
| Ophthalmoscopy | 18 | 1 |
| Diagnostic Tests | 18 | 1 |
| Fundus Fluorescein Angiography | 18 | 1 |
| Indocyanine Green Angiography | 19 | 1 |
| Ocular Coherence Tomography | 19 | 1 |
| Fundus Photography | 19 | 1 |
| Autofluorescence | 19 | 1 |
| Epidemiology | 20 | 2 |
| Prognosis and Disease Staging | 22 | 1 |
| Treatment Options | 22 | 1 |
| Pharmacological | 22 | 1 |
| Anti-VEGF Agents | 22 | 1 |
| Photodynamic Therapy | 23 | 1 |
| Treatment Algorithms and Prescribing Habits | 24 | 2 |
| Non-pharmacological Care | 26 | 1 |
| Laser Photocoagulation | 26 | 1 |
| Implantable Miniature Telescope | 26 | 1 |
| Transpupillary Thermotherapy | 27 | 1 |
| Surgical Therapy | 27 | 1 |
| Macular Degeneration Asia-Pacific Market to 2019 Marketed Products | 28 | 9 |
| Therapeutic Landscape | 29 | 1 |
| Lucentis (ranibizumab) Novartis AG/Roche (Genentech) | 29 | 1 |
| Eylea (aflibercept) Regeneron Pharmaceuticals/Bayer Healthcare | 30 | 2 |
| Avastin (bevacizumab) Genentech (Roche) | 32 | 1 |
| Macugen (pegaptanib sodium) Valeant Pharmaceuticals/Pfizer | 32 | 1 |
| Visudyne (verteporfin injection) Novartis AG | 33 | 1 |
| Triamcinolone Acetonide | 34 | 1 |
| Comparative Efficacy and Safety | 35 | 2 |
| Macular Degeneration Asia-Pacific Market to 2019 Pipeline for Disease | 37 | 11 |
| Overall Pipeline | 37 | 2 |
| Pipeline Analysis by Molecule Type | 39 | 2 |
| Pipeline Analysis by Mechanism of Action | 41 | 2 |
| Clinical Trials | 43 | 1 |
| Failure Rate | 43 | 1 |
| Clinical Trial Duration | 44 | 1 |
| Clinical Trial Size | 45 | 1 |
| Promising Drug Candidates in the Pipeline | 46 | 1 |
| MC-1101 MacuCLEAR, Inc. | 46 | 1 |
| KH902 (Fumintide) Chengdu Kanghong Pharmaceuticals Group Co., Ltd. | 46 | 2 |
| Macular Degeneration Asia-Pacific Market to 2019 Market Forecast to 2019 | 48 | 12 |
| Geographical Markets | 48 | 1 |
| APAC Market | 48 | 1 |
| Treatment Usage Patterns | 48 | 1 |
| Annual Cost of Treatment | 48 | 1 |
| Market Size | 48 | 2 |
| Australia | 50 | 1 |
| Treatment Usage Patterns | 50 | 1 |
| Annual Cost of Treatment | 50 | 1 |
| Market Size | 50 | 2 |
| China | 52 | 1 |
| Treatment Usage Patterns | 52 | 1 |
| Annual Cost of Treatment | 52 | 1 |
| Market Size | 52 | 2 |
| India | 54 | 1 |
| Treatment Usage Patterns | 54 | 1 |
| Annual Cost of Treatment | 54 | 1 |
| Market Size | 54 | 2 |
| Japan | 56 | 1 |
| Treatment Usage Patterns | 56 | 1 |
| Annual Cost of Treatment | 56 | 1 |
| Market Size | 56 | 2 |
| Drivers and Barriers for the Disease Market | 58 | 1 |
| Drivers | 58 | 1 |
| Geriatric Population to Drive Macular Degeneration Market | 58 | 1 |
| Strong Patent Protection of Dominant Drugs | 58 | 1 |
| Improvement in Diagnostic Techniques and Increase in Awareness | 58 | 1 |
| Barriers | 59 | 1 |
| Off-label Use of Avastin Impacts Annual Cost of Therapy | 59 | 1 |
| Poor Prescription Rates | 59 | 1 |
| High Failure Rate in Late Stage Clinical Trials | 59 | 1 |
| Macular Degeneration Asia-Pacific Market to 2019 Deals and Strategic Consolidations | 60 | 7 |
| Deals Analysis | 60 | 2 |
| Major Co-development Deals | 62 | 1 |
| Sinphar Enters into Co-development Agreement with MacuCLEAR | 62 | 1 |
| Allergan Enters into Co-development Agreement with Molecular Partners | 63 | 1 |
| X-Body BioSciences Enters into Co-development Agreement with Hengrui Medicine for AMD | 63 | 1 |
| Alcon Enters into Collaboration with AstraZeneca | 63 | 1 |
| Acucela Enters into Co-Development Agreement with Otsuka Pharma for ACU-4429 | 63 | 1 |
| Major Licensing Deals | 64 | 1 |
| Allegro Ophthalmics Enters into Licensing Agreement with Senju Pharma to Develop Integrin Peptide Therapy | 65 | 1 |
| Allergan Enters into Licensing Agreement with Molecular Partners | 65 | 1 |
| PanOptica Enters into Licensing Agreement with OSI Pharma | 65 | 1 |
| Lpath Enters into Licensing Agreement with Pfizer | 65 | 1 |
| Shionogi Enters into Licensing Agreement with OncoTherapy Science | 66 | 1 |
| Macular Degeneration Asia-Pacific Market to 2019 Appendix | 67 | 15 |
| All Pipeline Drugs by Phase | 67 | 5 |
| Discovery | 67 | 1 |
| Preclinical | 68 | 1 |
| IND-filed and Phase 0 | 69 | 1 |
| Phase I | 69 | 1 |
| Phase II | 70 | 1 |
| Phase III | 70 | 1 |
| Undisclosed | 71 | 1 |
| Market Forecasts to 2019 | 71 | 2 |
| Asia-Pacific | 71 | 1 |
| Australia | 71 | 1 |
| China | 72 | 1 |
| India | 72 | 1 |
| Japan | 72 | 1 |
| Market Definitions | 73 | 1 |
| Abbreviations | 73 | 2 |
| References | 75 | 2 |
| Research Methodology | 77 | 5 |
| Coverage | 77 | 1 |
| Secondary Research | 77 | 1 |
| Primary Research | 77 | 1 |
| Therapeutic Landscape | 78 | 1 |
| Epidemiology-based Forecasting | 78 | 2 |
| Market Size by Geography | 80 | 1 |
| Geographical Landscape | 81 | 1 |
| Pipeline Analysis | 81 | 1 |
| Expert Panel Validation | 81 | 1 |
| Contact Us | 81 | 1 |
| Disclaimer | 81 | 1 |
